Share price · UCBJY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when UCBJY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 31 Jul 2026+2.9%
Nothing announced by UCBJY that day or the session before.
- 30 Jul 2026-12.6%
Nothing announced by UCBJY that day or the session before.
- 15 Jun 2026-5.4%
Nothing announced by UCBJY that day or the session before.
- 28 Apr 2026-5.3%
Nothing announced by UCBJY that day or the session before.
- 21 Apr 2026-6.2%
Nothing announced by UCBJY that day or the session before.
- 26 Feb 2026-7.9%
Nothing announced by UCBJY that day or the session before.
- 12 Feb 2026+2.9%
Nothing announced by UCBJY that day or the session before.
- 6 Jan 2026+7.2%
Nothing announced by UCBJY that day or the session before.
- 31 Oct 2025-5.9%
- 28 Oct 2025-5.7%
Nothing announced by UCBJY that day or the session before.
Share of unusual movement by asset
For each asset, the share of UCBJY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(16 total)
| Target & Modality | |||
|---|---|---|---|
bimekizumab(Bimzelx) | Approved | IL-17A/FMonoclonal antibody | Psoriatic ArthritisPsoriasisHidradenitis Suppurativa |
| Approved | Synaptic vesicle glycoprotein 2A (SV2A)Small molecule | Epilepsy Focal Onset Seizures | |
certolizumab pegol(Cimzia) | Approved | TNF-alphaAntibody fragment | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis Crohn's Disease |
Fenfluramine(Fintepla) | Approved | Serotonin 5-HT2 receptorsSmall molecule | EpilepsyRett SyndromeDevelopmental and Epileptic EncephalopathiesDravet SyndromeLennox-Gastaut Syndrome |
Lacosamide(Vimpat) | Approved | Voltage-gated sodium channelsSmall molecule | Epilepsy Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures |
| Approved | Synaptic vesicle protein 2A (SV2A)Small molecule | Epilepsy Focal Onset Seizures | |
| Approved | Synaptic vesicle protein 2A (SV2A)Small molecule | Epilepsy Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures | |
| Approved | GABA-A receptor · GABA-A receptor (benzodiazepine site)Small molecule | Epilepsy | |
| Approved | dopamine precursorSmall molecule | Parkinson's Disease | |
rotigotine(Neupro) | Approved | Dopamine receptorsSmall molecule | Parkinson's Disease |
| Phase 3 | GABA-A receptorSmall molecule | Epilepsy | |
| Phase 2 | Tau (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease | |
| Phase 2 | IL-13, IL-17A, IL-17FMultispecific antibody | Atopic Dermatitis | |
| Phase 2 | D1 receptorSmall molecule | Parkinson's Disease | |
| Phase 1 | BCMA x CD3Multispecific antibody | Systemic Lupus Erythematosus |
Discontinued programmes (2)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (5)
March 2027 (2)
May 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (3)
2029 (4)
February 2029 (2)
June 2029 (1)
What to watch
November 2029 (1)
What to watch
2030 (1)
July 2030 (1)
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (5)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $3.8B | $939M | $1.9B | — | report ↗ |
UCB reported revenue of $3,809.22M, up 26.2% YoY, R&D spend of $939.47M, up 10.1% YoY, and cash and equivalents of $1,889.3M for H1 2025.
Figures only: this period's report disclosed no narrative text
View 4 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-H1 | $3.0B | $853M | $458M | — | report ↗ |
| 2023-H1 | $2.8B | $821M | $497M | — | report ↗ |
| 2022-H1 | $3.2B | $873M | $538M | — | report ↗ |
| 2021-H1 | $3.3B | $908M | $676M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $8.8B | — | — | — | report ↗ |
Insider transactions
Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 7 reporting institutions held 0.0M shares ($1.4M, 0.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RHUMBLINE ADVISERS | 7,496 | $1.1M |
| 2 | GAMMA Investing LLC | 1,696 | $256K |
| 3 | PNC FINANCIAL SERVICES GROUP, INC. | 275 | $41K |
| 4 | Salomon & Ludwin, LLC | 96 | $15K |
| 5 | NBC SECURITIES, INC. | 10 | $1K |
| 6 | Ancora Advisors LLC | 4 | $603 |
| 7 | HANTZ FINANCIAL SERVICES, INC. | 68 | $10 |